文献速递抗栓抗凝管理药物不良反应与药物警戒

退伍军人联合抗栓治疗中质子泵抑制剂使用情况及简化出血风险评分验证

Proton Pump Inhibitor Utilization in Veteran Patients on Combined Antithrombotic Therapy and Validation of Simplified Bleeding Risk Score.
PubMed 文献 · Pharmacotherapy · 2020-11-25

本研究回顾性纳入2018年间启动联合抗栓治疗的退伍军人患者,描述质子泵抑制剂(PPI)使用现状并探索胃肠道出血预测因素。结果显示PPI联用率为40.9%,仅22.3%用于胃肠道出血预防;简化五因子风险评分(FFRS)预测胃肠道出血的C统计量为0.738,优于HAS-BLED的0.596。

要点

  • 联合抗栓治疗患者PPI联用率为40.9%(484/1181),仅22.3%用于胃肠道出血预防。
  • 当前饮酒、吸烟、慢性肾病、消化性溃疡病和非甾体抗炎药使用是胃肠道出血的显著预测因素。
  • 简化FFRS预测胃肠道出血的C统计量为0.738(95%CI 0.684-0.787),优于HAS-BLED的0.596(95%CI 0.538-0.653)。

核心结论

  • 退伍军人联合抗栓治疗患者中PPI联用率低于现有指南推荐,仅22.3%用于胃肠道出血预防。
  • 简化FFRS模型预测胃肠道出血的总体性能优于HAS-BLED评分,但仅为探索性验证。

研究设计与样本

  • 共纳入1181例患者,其中484例(40.9%)接受PPI联用治疗。

主要发现

  • PPI联用率为40.9%(484/1181),仅22.3%的联合抗栓治疗患者使用PPI用于胃肠道出血预防。
  • PPI使用者与PPI联用者的平均随访时间无差异(264.01天 vs 271.92天;p=0.3761)。
  • 多因素分析显示当前饮酒(p=0.005)、当前吸烟(p=0.022)、慢性肾病(p=0.004)、消化性溃疡病(p<0.001)和非甾体抗炎药使用(p=0.048)是胃肠道出血的显著预测因素。
  • 简化FFRS预测胃肠道出血的C统计量为0.738(95%CI 0.684-0.787),HAS-BLED为0.596(95%CI 0.538-0.653),组间比较p=0.0094。

关键数值与推荐

  • 简化FFRS预测胃肠道出血的C统计量为0.738(95%CI 0.684-0.787)。
  • HAS-BLED评分预测胃肠道出血的C统计量为0.596(95%CI 0.538-0.653)。

临床怎么用

  • 对联合抗栓治疗患者应评估胃肠道出血风险,考虑PPI用于预防的高危患者识别不足。
  • 简化FFRS可作为胃肠道出血风险分层工具,但需进一步验证后方可用于临床决策。

局限性

  • 本研究为回顾性设计,仅纳入退伍军人患者,结果外推性受限。
  • FFRS验证为探索性分析,需在前瞻性队列中进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concomitant use of anticoagulant and antiplatelet agents can increase the risk of gastrointestinal bleed (GIB). Use of proton pump inhibitors (PPIs) has been proposed to decrease the risk of GIB in patients on combined antithrombotic therapy (CAT). OBJECTIVE: To describe the current utilization of PPIs in veteran patients on CAT and associated clinical predictors of GIB. METHODS: This retrospective study included patients on CAT receiving PPIs, with at least one of the CAT agents initiated between January 1, 2018 and October 30, 2018. Data were extracted from the computerized patient record system. Primary end point included estimating proportion of patients on CAT receiving PPI co-therapy, describing patient characteristics, and identifying clinical predictors of GIB. Secondary outcomes included reporting GIB events and all-cause mortality. Additional outcome was to validate the five-factor risk score (FFRS) for GIB in patients on CAT and compare its overall predictive performance to HAS-BLED score. RESULTS: This study reports an overall rate of PPI co-therapy in patients on CAT of 40.9% (484/1181), with only 22.3% of patients on CAT receiving PPI for GIB prophylaxis. There was no difference in the mean follow up duration of PPI users and PPI co-therapy (264.01 vs 271.92 days; p=0.3761). Current alcohol use (p=0.005), current smokers (p=0.022), chronic kidney disease (p=0.004), peptic ulcer disease (p<0.001), and non-steroidal anti-inflammatory drug use (p=0.048) were significant predictors of GIB in multivariate analyses of our study cohort. We further provide exploratory validation that use of a simplified FFRS to predict GIB showed a trend towards better overall predictive performance as compared to HAS-BLED score (C-statistic: 0.738; 95% CI 0.684-0.787 for FFRS vs C-statistic: 0.596; 95% CI 0.538-0.653 for HAS-BLED; p=0.0094). CONCLUSION: This study reports lower rate of PPI co-therapy in veteran patients on CAT per currently available guidance. Further we explore utilization of simplified FFRS model to predict GIB in patients on CAT with long-term PPI co-therapy.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Patil T, Murphy K, Woodard L, et al. Proton Pump Inhibitor Utilization in Veteran Patients on Combined Antithrombotic Therapy and Validation of Simplified Bleeding Risk Score. Pharmacotherapy. 2020. PMID: 33073362. doi:10.1002/phar.2477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。